"Alarming" Drop In Russian Drug Production

8 September 1996

With another drop in volume production of 10% so far this year after a 40% downturn in 1995, the situation in the Russian pharmaceutical industry is "alarming," according to Aleksei Vilken, Deputy Health Minister for the Russian Federation.

Speaking to the journal Farmatsevtichesky Vestnik, Mr Vilken said the industry had never been especially strong but that the government is now considering moves that would "put production back on track." He added that there are Russian drug producers doing well, such as Ferane, Akrikhin, Moskhimfarmpreparaty, Tatkhimfarmpreparaty and some others, but they are not numerous.

The Minister said the problem is raw drugs production. Most of the companies in this sector had closed down in the wake of losses and some were on their last legs, such as Usolye-Sibirskoye and Anzhero-Sudzhensk. Mr Vilken said the government had to "stop at nothing" to save the sector which was the basis of production.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight